REGiMMUNE Limited: REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting
RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GvHD REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative